Clinical Scorecard: Perspectives on Medicare’s Proposed iDose TR Coverage Policy
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Sustained drug-delivery therapies for glaucoma management. |
| Target Population | Patients with glaucoma who have failed medical management and selective laser trabeculoplasty. |
| Care Setting | Ophthalmology practice and surgical settings. |
Key Highlights
- Proposed LCDs require failure of at least 2 topical medications and SLT before considering iDose TR.
- Implantation may not occur concurrently with other ophthalmic surgeries, except cataract surgery.
- Concerns raised about the proposed LCDs not reflecting contemporary glaucoma practices.
- Experts argue procedural pharmaceuticals should not be treated like MIGS procedures.
- The public comment period for the proposed LCDs ended on July 4, 2026.
Guideline-Based Recommendations
Diagnosis
- Assess patient history and previous treatments for glaucoma.
Management
- Consider iDose TR after failure of topical medications and SLT.
Monitoring & Follow-up
- Evaluate patient response to treatment and adjust management as necessary.
Risks
- Potential for increased costs and patient burden if multiple procedures are required.
Patient & Prescribing Data
Patients with glaucoma requiring advanced treatment options.
Sustained drug delivery may reduce the need for additional surgeries and improve compliance.
Clinical Best Practices
- Utilize evidence-based guidelines for glaucoma treatment.
- Consider individual patient circumstances when determining treatment pathways.
- Advocate for policies that reflect the clinical realities of glaucoma management.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







